GSK's new ICS/LABA Wanrui Shu is listed in China

GSK China announced on June 28 that its new ICS/LABA drug Wan Ruishu (common name: fluorocaron/Virantero, FF/VI) has officially entered the Chinese market.As the only ICS/LABA drug on the market once a day, Wan Ruishu helps improve the management of chronic respiratory diseases.it is known that Wan Ruishu is a compound preparation consisting of inhaled corticosteroid (ICS) fluorocardosong "FF" and long-acting beta-2 astigation (LABA) Virantero "VI" (FF/VI), which contains two drug components that interact to help more asthma patients improve asthma control and reduce acute exacerbation in moderate to severe chronic lung disease.Xin, a professor of respiratory medicine at the First People's Hospital affiliated with Shanghai Jiaoda University, said:Asthma has a large prevalence base in China, and the prevalence rate is increasing year by year, but the disease control situation is not good." How to further improve asthma control and improve the quality of life of patients is an urgent problem to be solved in asthma diagnosis and treatment in China. The launch of the new ICS/LABA Wanruishu will provide clinicians with new solutions to further improve asthma control in patients. According to the latest epidemiological survey, there are now more than 30 million asthma cases in China. According to the asthma control level classification defined by GINA, the overall asthma control rate in urban areas of China is 28.5%, and the asthma control rate is expected to be lower in remote areas and primary hospitals.
and the increasing cost of treating asthma has brought great financial burden to patients, but also caused many indirect losses such as work-out, mis-study, psychological disorders and reduced quality of life. GSK, a global healthcare company that has been introducing innovative respiratory drugs for two years, has high hopes for Wan ruishu."GSK has 50 years of experience in the field of chronic respiratory diseases worldwide," said Dr. He Li Mirror, GSK's head of Medical Affairs and Vice President for China. Since the introduction of the first short-acting bronchid trachea thybosis in the Chinese market in 1988, GSK has been helping China's respiratory adhesive management and development for more than 30 years.For more than 30 years, GSK has successfully brought innovative drugs from one breathing field after another to China for the benefit of more patients, from the first inhaled steroids used to treat asthma to the first ICS/LABA drug to the one-day inhalation drug WanRuishu.We are pleased that Wan Ruishu is listed in China to help improve disease control and quality of life for patients in China. (Xinhua) --